This phase III single-arm, open-label, 48-week study will evaluate a 3-month injectable suspension as the OFS + tamoxifen or an AI in patients with HR-positive, HER2-negative breast cancer [78]. This evidence concerns the gene ERBB2 and breast carcinoma.